treatment News

TORONTO, Ontario – Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), today announced the publication of a retrospective analysis of patients living with amyotrophic lateral sclerosis (ALS) in Muscle and Nerve.1 The analysis evaluated patients taking RADICAVA® Oral Suspension (edaravone) compared with Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) 2 historical...
Chicago, Ill. – The lab of Yongchao C. Ma, PhD, at Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago uncovered a novel mechanism that leads to motor neuron degeneration in spinal muscular atrophy (SMA). This discovery offers a new target for treatment that...
SOUTH BEND, Ind.– Indiana University School of Medicine researchers at the school’s South Bend regional campus, in collaboration with colleagues at the University of Notre Dame, have identified a new therapeutic target for pulmonary hypertension, a type of high blood pressure that affects the blood vessels in the lungs. Their...
A new cognitive test for detecting Alzheimer’s disease is quicker and more accurate than many current tests, and could help diagnose early dementia, concludes a study published on bmj.com today. An estimated 24 million people throughout the world have dementia and the number affected will double every 20 years. Early...
Vienna, Austria – A research team led by Georg Stary (Medical University of Vienna and CeMM) has identified a new approach to treating the inflammatory disease sarcoidosis. In a clinical study, the inhibition of a specific signaling pathway showed clear success in the treatment of granulomas in the skin. This...
BALTIMORE, Maryland — Researchers at Kennedy Krieger Institute have made significant strides in improving the lives of patients with Tourette syndrome. Their recent publication highlights how behavioral therapies—an approach that teaches patients how to manage certain tics using behavioral strategies—are proving to be the most effective treatment. Tourette syndrome (TS),...
WALTHAM, Mass. — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch and uptake of new anti-amyloid monoclonal antibodies, most notably Elan/Wyeth’s bapineuzumab and Eli Lilly’s solanezumab, will be the main driver of robust 11 percent annual growth from...